Market Size (2019)
—
Vertical: HealthcareBase Year: 201912 Sections
Market Size (2019)
—
Projected (2027)
—
CAGR (2017–2027)
N/A
Key Players
9+
1.1. Market Attractiveness Analysis
1.1.1. Global Seborrheic Dermatitis Treatment Market, by Treatment Type
1.1.2. Global Seborrheic Dermatitis Treatment Market, by Route of Administration
1.1.3. Global Seborrheic Dermatitis Treatment Market, by End User
1.1.4. Global Seborrheic Dermatitis Treatment Market, by Region
Global seborrheic dermatitis treatment market is expected to grow at 10.6% CAGR during the forecast period, 2020-2027.
· 2019: USD XXXX Million (Approx.)
· 2027: USD XXXX Million (Approx.)
CAGR (2020–2027)
· 10.6% (Approx.)
Key Market Drivers
· Rise in awareness about seborrheic dermatitis treatment
· The growing global geriatric population that are most affected by seborrheic dermatitis
Key Market Opportunities
· XXXXXXXXXXXXX
Key Vendors
· Sonoma Pharmaceuticals
· Merck
· Hikma Pharmaceuticals
· Allen and Hanburys
· GlaxoSmithKline
· Bausch Health
· Valent Pharmaceutical
· West-Ward Pharmaceutical Corp
· Others
1.1 market attractiveness analysis Global SEBORRHEIC DERMATITIS TREATMENT MARKET, By TREATMENT TYPE Global SEBORRHEIC DERMATITIS TREATMENT MARKET, by TREATMENT TYPE, 2019 (%)
Seborrheic Dermatitis Treatment Market is a key focus area for market intelligence and strategic research.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSeborrheic dermatitis is a chronic inflammatory disorder that mostly affects the head and face. Primarily environmental, genetic, and general health problems are the cause of this disorder. The exact cause of seborrheic dermatitis remains unknown, but factors such as a change in hormone is the primary cause of this disease. It frequently affects people post-puberty.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe research starts with the extensive procurement process of data/information and statistics from company annual reports, government websites, statistics agencies, and paid databases. This information creates a base for the study. The information also helps to define the scope and to narrow down the area for study for the market. This raw information is processed and analyzed to extract crisp data points which currently affect or are likely to affect the industry during the forecast period. After analyzing the information, a proprietary statistical tool is used for market estimation and forecast, which generates the quantitative figures/sizes of the market/sub-segments in the current scenario as well as for the forecast period.
After estimating the market sizes and estimates, the numbers are verified with industry participants and key opinion leaders. The wide network of industry participants add value to the research and verify the numbers and estimates provided in the study. At the last stage of the research process, a final report is prepared, which is then published on different websites as well as distributed through various channels. The below figure contains the different stages of the research process to produce the report.
DATA MINING
Data mining is an extensive part of our research process. It involves the procurement of market data and related information from different verified and credible sources. This step helps to obtain raw information about the product of the industry and their types, the monetary process for different end uses, the pool of market participants, and the nature of the industry and scope of the study. The data mining stage comprises both primary and secondary sources of information.
SECONDARY RESEARCH
In the secondary research process, various sources are used to identify and gather industry trends and information for the research process. We at Wantstats have access to some of the most diversified and extensive paid databases, which give us the most accurate data/information on markets sizes, product, and pricing. Mentioned below is a detailed list of sources that have been used for this study. Please note that this list is not limited to the names as mentioned; we also access other data sources depending on the need.
Market Sizing & Revenue
Qualitative Information & Trends
Company Websites
· White Papers
· Magazines
· Company Websites
· Annual Reports
· Press Releases
· Investor Presentations
· Paid Databases
· Authenticated Directories
· Independent Studies
· Internal Audit Reports & Archives
· Government and Regulatory Published Material
· American Data Security Authority
· Seborrheic Dermatitis Treatment Advocacy Network.
· XXXXX
· XXXXX
Annual Reports
Investor Presentations
Authenticated Directories
Hoover’s, Factiva, Bloomberg
PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
Respondents
Data Points Received
Manufacturers
· Market Size
· Top of the Mind Key Market Players
· Direct Competitors
· Company Market Shares
· Growth Rate (%)
· Market Trends and Prominent Market Drivers
· Major Products
· Product Cost
· Commercial Availability
· Upcoming Technologies
End User
· Product Cost
· Adoption Rate & Maintenance Cost
BREAKDOWN OF PRIMARY RESPONDENTS
FORECASTING METHODS
We at Wantstats follow an extensive process for arriving at market estimations, which involves the use of multiple forecasting Methods as mentioned below.
Forecasting Methods
Description
Qualitative and Quantitative Analysis
A combination of qualitative approach, i.e., primary interviews with industry experts to understand the interviewees’ opinions and judgments, more commonly known as the Delphi method, and quantitative analysis to forecast future data based on historical and current data.
Weighted Average Approach
Via this approach, future data is calculated based on the mean of the past data under the assumption that some factors affecting the market in the past will continue to have a similar impact in the future.
Drift Method
This approach is used to vary the forecast, that is increase or decrease market factor over time depending on various parameters affecting the change in the trends of the market.
Time Series Methods
Integration of several time series methods such as moving average, moving weighted average, linear prediction, and trend estimation are applied while determining the year-on-year growth rate and the compound annual growth rate of the market being studied.
Causal/Econometric Forecasting Methods
Various economic factors such as inflation rate, fiscal policies, changes in government regulations, taxes, labour costs, and interest rates are taken into consideration while determining the current market size and predicting the future market growth rate.
Judgmental Methods
This involves collection of intuitive judgment, opinions, and probability estimates from industry experts in the case of new or upcoming markets/technologies for which no prior data is available.
Regression Analysis
This type of statistical modelling is carried out for predicting and forecasting dependent and independent variables that will directly or indirectly impact the market.
Probabilistic Forecasting
This forecasting method is carried out to assign a probability to every possible outcome ranging from the least optimistic to highly optimistic, which helps in gauging the market under stable conditions.
PESTLE Analysis
Political, economic, social, technological, legal, and environmental factors are taken into consideration while deriving the fluctuations in the growth rate of the market.
Porter’s Five Forces Analysis
By understanding the supplier-side and demand-side factors, the current market scenario can be estimated, and future market scenario predicted, which aid in deriving the growth rate of the market.
RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
Understanding and penetrating the market in terms of valuation is crucial task in the process of business research. This again becomes significantly important while investing and choosing the business opportunities. In this regard, we at Wantstats performs two ways market sizing approach simultaneously namely top-down and bottom-up approaches. In this step, we place different data points, numeric attributes, information and industry trends at an appropriate space to deduce the estimates & forecast values over the coming years. We use different mathematical models to estimate the market sizes of different economies and segments. Each of which is further summed up to define the total market.
We at Wantstats owns a proprietary statistical tool for market estimations which helps us to comprehend market size estimates & forecasts for different markets and industries.
In the bottom-up approach, the revenue of key companies and their shares in the market is assessed to deduce the market size. More than 80% key players operating in the polyp’s market is studied. The segmental revenue of each player is analyzed and the market size for seborrheic dermatitis treatment’ market is extracted from the segmental/product revenue with the help of secondary and primary research. This extracted market size for seborrheic dermatitis treatment’ market is then validated from industry experts and partner consultants. This derived market size contributes around 65 – 70% of the total global market share in terms of revenue for seborrheic dermatitis treatment’ market. Using the diagnosis of data triangulation method, the overall global market size is estimated.
TOP-DOWN APPROACH
This overall market size is then used in the top-down procedure to estimate the size of the other sub-markets with the help of percentage splits of the market segments from secondary and primary research. The demand side analysis is conducted in which spent analysis for major industries in each region is studied. The end-users considered in the scope of this research study contributes around 70 % of the total in the polyp’s market.
The countries considered in the scope of Seborrheic dermatitis treatment market are US, Canada, Mexico, the UK, Germany, France, Italy, Spain, Switzerland, Austria, Belgium, Denmark, Finland, Greece, Hungary, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Slovakia, Sweden, Romania, Ireland, China, Japan, Malaysia, Indonesia, the Philippines, South Korea, Singapore, India, Australia & New Zealand, South Africa, Egypt, Nigeria, Saudi Arabia, Qatar, the UAE, Bahrain, Kuwait, and Oman, Brazil, Argentina, Chile, and others. However, the number of countries vary from devices to devices and it solely depends on the product approvals in the respective countries and the commercial availability of the products.
Below figure explains the process of market estimation using independent tool employed by our analysts to get the sizing of the market.
DATA TRIANGULATION
After arriving at the overall market sizes, the total market is divided into several segments and sub segments. Again, market breakdown and data triangulation procedures are implemented wherever applicable, to complete the overall market engineering process and to collect the exact statistics for all segments and sub-segments. The data was triangulated by studying various factors and trends from both demand and supply sides. Along with this, the market was validated by using both top-down and bottom-up approaches.
VALIDATION
Validation is the most important stage of the report making process. Validation via an intricately designed feedback process helps us to finalize the sizing estimates and forecast for the final collation. Extensive primary research is performed to verify the information. This includes telephonic & personal interviews, mails, feedback forms, questionnaires and polling options/answers with the group of relevant people. Validation helps to duly check the authenticity of the key industry trends, market dynamics, company market share, different business models & their conclusions.
Base Year
2019
Historical Period
2017 – 2018
Forecast Period
2020 – 2027
Primary Interviews
150+
Historical data (2017–2019) and forecast period (2019–2027)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
The global polyp’s market is characterized by the presence of many regional and local vendors……………………
1.1 global SEBORRHEIC DERMATITIS TREATMENT MARKET: Company Share Analysis
1.1 Competitor Dashboard
1.1 Major growth strategy in the Global SEBORRHEIC DERMATITIS TREATMENT MARKET
1.1 The Leading Player in terms of Number of Developments in Global SEBORRHEIC DERMATITIS TREATMENT MARKET
TABLE 1 The most active player in the Global SEBORRHEIC DERMATITIS TREATMENT MARKET
Company Name
Contracts & Agreements
Mergers & Acquisitions
New Product Development
Expansions & Investments
Total
Player 1
XX
XX
XX
XX
XX
Player 2
XX
XX
XX
XX
XX
Player 3
XX
XX
XX
XX
XX
Player 4
XX
XX
XX
XX
XX
Player 5
XX
XX
XX
XX
XX
Player 6
XX
XX
XX
XX
XX
Player 7
XX
XX
XX
XX
XX
Player 8
XX
XX
XX
XX
XX
Player 9
XX
XX
XX
XX
XX
Player 10
XX
XX
XX
XX
XX
Total
XX
XX
XX
XX
XX
1.1 Key Developments & Growth Strategies New product Launch/service Types
1.2 Major Players Financial Matrix & Market ratio Sales & operating Income
See plans for professionals or small and medium businesses.

Analytical insights on Seborrheic Dermatitis Treatment Market covering market dynamics, competitive landscape, and strategic outlook.
Seborrheic Dermatitis Treatment Market represents a significant market opportunity with multiple growth drivers across regions and segments.
The Seborrheic Dermatitis Treatment Market market encompasses 4 key regions and multiple market segments, with the study period spanning 2017 to 2027.
The market is segmented across multiple dimensions, with detailed breakdowns available by component, region, and application type to support strategic planning and investment decisions.
This report profiles 9 key companies operating in the Seborrheic Dermatitis Treatment Market market, covering market positioning, product portfolios, and recent developments.
Leading players include Koninklijke Philips N.V., BECKMAN COULTER, INC., Thermo Fisher Scientific Inc. , Randox Laboratories Ltd, F. Hoffmann-La Roche AG, and 4 others.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 104 companies operating in the Seborrheic Dermatitis Treatment Market market, including revenue, employee count, and market positioning where available.
Showing 104 of 104 companies
Advanced Instruments — Healthcare
Ginevri — Healthcare
Drägerwerk AG & Co — Healthcare
Randox Laboratories Ltd — Healthcare
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million. --- ### Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased) Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases). The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond. ### Independent characterization Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers. The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products. The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer. The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain. **Value-chain position.** Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company. **Customer types:** large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell). **End-markets served:** small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents. ### Revenue model mix (FY2021–FY2025) *Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.*
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Historical performance and future projections (2020–2030, USD Billion)